Use of tilmicosin in a severe outbreak of respiratory disease in weaned beef calves.
Severe respiratory disease, associated with seroconversion to bovine respiratory syncitial virus (BRSV), caused the death of two cattle and necessitated antibiotic treatment of 70 calves (rectal temperature of 39.6 degrees C or greater) from a group of 96 (73%) during an 8-day period. Tilmicosin injection resulted in a reduction in median rectal temperature from 40.3 degrees C to 39.2 degrees C and 39.0 degrees C for the first and second days after treatment. The rectal temperature was 39.5 degrees C or lower in 72% (48 of 67) and 96% (64 of 67) of cattle 1 and 2 days after tilmicosin treatment, respectively. Ten cattle were re-treated with tilmicosin 6 to 16 days after the first treatment. Our study demonstrated that bovine respiratory syncytial virus infection could cause severe respiratory disease in a beef herd that had no previous history of BRSV-related disease. Secondary bacterial invasion after BRSV infection was controlled effectively by tilmicosin treatment but repeat antibiotic treatments were occasionally necessary due to bacterial re-infection of the respiratory tract.
Scott
P R
PR
Department of Veterinary Clinical Studies, Royal (Dick) School of Veterinary Studies, Roslin, Midlothian, Scotland.
McGowan
M
M
Sargison
N D
ND
Penny
C D
CD
Lowman
B G
BG
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001831:Body Temperature / Q000187:drug effects; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000453:epidemiology; D003002:Clonixin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004196:Disease Outbreaks / Q000662:veterinary*; D018942:Macrolides; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000188:drug therapy / Q000662:veterinary*; D012606:Scotland / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome; D015645:Tylosin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D018942:Macrolides; C014557:flunixin; D003002:Clonixin; C052319:tilmicosin; D015645:Tylosin